MCID: BLD039
MIFTS: 37

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 72
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 50 C39836 C4032
UMLS 72 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to clear cell adenocarcinoma and villous adenoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and colon, and related phenotype is neoplasm.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 204, show less)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 30.2 KRT7 KRT20
2 villous adenoma 30.1 KRT20 CDX2
3 linitis plastica 29.8 KRT7 KRT20
4 tubular adenocarcinoma 29.6 KRT20 CDX2
5 mammary paget's disease 29.6 KRT7 KRT20
6 inverted papilloma 29.5 KRT7 KRT20
7 mucinous cystadenocarcinoma 29.4 KRT7 KRT20
8 carcinosarcoma 29.4 KRT7 HRAS CTNNB1
9 transitional cell carcinoma 29.1 KRT7 KRT20 HRAS
10 appendix adenocarcinoma 29.1 KRT7 KRT20 CDX2
11 mucinous adenocarcinoma 29.1 KRT7 KRT20 CDX2
12 cystadenocarcinoma 29.1 KRT7 HRAS FBXW7
13 rectum adenocarcinoma 28.7 KRT7 KRT20 CDX2
14 adenocarcinoma in situ 28.7 KRT7 KRT20 CDX2
15 signet ring cell adenocarcinoma 28.7 KRT7 KRT20 CDX2
16 endometrial cancer 28.6 UCA1 KRT7 HRAS CTNNB1
17 gastric cancer 28.6 UCA1 KRT20 CTNNB1 CDX2
18 cystitis cystica 28.4 KRT7 KRT20 CTNNB1 CDX2
19 glandular cystitis 28.4 UCA1 KRT7 KRT20 CDX2
20 colorectal adenocarcinoma 27.8 KRT7 KRT20 HRAS CTNNB1 CDX2
21 gastric adenocarcinoma 27.6 KRT7 KRT20 HRAS CTNNB1 CDX2
22 lung cancer susceptibility 3 27.6 KRT7 KRT20 HRAS CTNNB1 CDX2
23 pelvic lipomatosis 11.3
24 bladder clear cell adenocarcinoma 11.3
25 bladder signet ring cell adenocarcinoma 11.3
26 bladder colonic type adenocarcinoma 11.3
27 bladder urachal adenocarcinoma 11.3
28 bladder tubulo-cystic clear cell adenocarcinoma 11.3
29 bladder papillary clear cell adenocarcinoma 11.3
30 bladder hepatoid adenocarcinoma 11.3
31 adenocarcinoma 10.7
32 gallbladder adenoma 10.4 HRAS CTNNB1
33 goblet cell carcinoid 10.3 KRT20 CTNNB1
34 bladder cancer 10.3
35 skin squamous cell carcinoma 10.2 HRAS FBXW7
36 hepatoid adenocarcinoma 10.2
37 hydronephrosis 10.2
38 nephrogenic adenoma 10.2
39 serous cystadenocarcinoma 10.1 HRAS FBXW7
40 urachal adenocarcinoma 10.1
41 vaginal tubulovillous adenoma 10.1 KRT20 CDX2
42 vaginal adenoma 10.1 KRT20 CDX2
43 vaginal benign neoplasm 10.1 KRT20 CDX2
44 colorectal adenoma 10.1 HRAS CTNNB1
45 skin benign neoplasm 10.1 KRT20 HRAS
46 endometriosis 10.1
47 papillary craniopharyngioma 10.1 KRT7 CTNNB1
48 craniopharyngioma 10.1 KRT7 CTNNB1
49 uterine carcinosarcoma 10.1 HRAS FBXW7 CTNNB1
50 exstrophy of bladder 10.1
51 rare tumor 10.1
52 adenomyoma 10.0 KRT7 CTNNB1
53 female reproductive endometrioid cancer 10.0 KRT7 CTNNB1
54 pulmonary sclerosing hemangioma 10.0 KRT7 CTNNB1
55 sclerosing hemangioma 10.0 KRT7 CTNNB1
56 schistosoma mansoni infection, susceptibility/ 10.0
57 schistosomiasis 10.0
58 cystitis 10.0
59 ovarian serous cystadenocarcinoma 10.0 HRAS FBXW7
60 cystadenoma 10.0 KRT7 KRT20
61 acinar cell carcinoma 10.0 KRT7 CTNNB1
62 cystic basal cell carcinoma 9.9 KRT7 KRT20
63 prostate squamous cell carcinoma 9.9 KRT7 HRAS
64 malignant syringoma 9.9 KRT7 KRT20
65 transverse colon cancer 9.9 KRT7 KRT20
66 seminal vesicle adenocarcinoma 9.9 KRT7 KRT20
67 krukenberg carcinoma 9.9 KRT7 KRT20
68 eyelid carcinoma 9.9 KRT7 KRT20
69 papillary transitional carcinoma 9.9 KRT7 KRT20
70 small cell carcinoma 9.9 KRT7 KRT20
71 small cell carcinoma of the bladder 9.9 KRT7 KRT20
72 intratubular embryonal carcinoma 9.9 KRT7 KRT20
73 adenoid squamous cell carcinoma 9.9 KRT7 KRT20
74 bladder diverticulum 9.9
75 breast cancer 9.9
76 pyelonephritis 9.9
77 squamous cell papilloma 9.9
78 papilloma 9.9
79 acute kidney failure 9.9
80 bladder colloid adenocarcinoma 9.9
81 vaginal discharge 9.9
82 pituitary adenoma 9.9
83 urinary tract obstruction 9.9
84 kidney disease 9.9
85 bladder urachal carcinoma 9.9
86 peritonitis 9.9
87 squamous cell carcinoma 9.9 UCA1 HRAS CTNNB1
88 bile duct adenoma 9.9 KRT7 KRT20
89 bile duct cystadenocarcinoma 9.9 KRT7 KRT20
90 vulval paget's disease 9.9 KRT7 KRT20
91 meibomian cyst 9.9 KRT7 KRT20
92 papillary serous adenocarcinoma 9.9 KRT7 KRT20
93 mixed cell type cancer 9.9 KRT7 HRAS
94 rectum cancer 9.9
95 colon adenocarcinoma 9.9
96 adenoma 9.9
97 bladder lymphoma 9.9 KRT7 KRT20
98 glycogen-rich clear cell breast carcinoma 9.9 KRT7 KRT20
99 medulloepithelioma 9.9 KRT7 KRT20
100 renal pelvis carcinoma 9.9 KRT7 KRT20
101 paget disease, extramammary 9.9 KRT7 KRT20
102 lymphoepithelioma-like carcinoma 9.9 KRT7 KRT20
103 teratoma 9.9 KRT7 CDX2
104 cystadenofibroma 9.9 KRT7 KRT20
105 infiltrative basal cell carcinoma 9.9 KRT7 KRT20
106 bile duct adenocarcinoma 9.9 KRT7 HRAS
107 dermoid cyst 9.9 KRT7 KRT20
108 eccrine sweat gland neoplasm 9.9 KRT7 KRT20
109 ovary adenocarcinoma 9.9 KRT7 HRAS
110 ovary neuroendocrine neoplasm 9.9 KRT7 CDX2
111 intestinal benign neoplasm 9.9 HRAS CTNNB1 CDX2
112 bladder disease 9.9 UCA1 KRT20
113 thymus lipoma 9.9 KRT7 KRT20
114 colonic disease 9.9 HRAS CTNNB1 CDX2
115 ovarian cystic teratoma 9.9 KRT7 KRT20
116 intestinal disease 9.9 HRAS CTNNB1 CDX2
117 immune system organ benign neoplasm 9.8 KRT7 KRT20
118 anus adenocarcinoma 9.8 KRT7 CDX2
119 mucinous adenofibroma 9.8 KRT7 CDX2
120 epithelial predominant wilms' tumor 9.8 KRT7 CDX2
121 duodenum adenocarcinoma 9.8 KRT7 CDX2
122 large cell neuroendocrine carcinoma 9.8 KRT7 KRT20
123 nasal cavity cancer 9.8 KRT7 CDX2
124 lung benign neoplasm 9.8 KRT7 HRAS
125 mucinous ovarian cystadenoma 9.8 KRT7 CDX2
126 pancreatic ductal carcinoma 9.8 KRT7 KRT20
127 ovary epithelial cancer 9.8 KRT7 HRAS
128 malignant ovarian surface epithelial-stromal neoplasm 9.8 KRT7 HRAS
129 ovarian brenner tumor 9.8 KRT7 KRT20
130 myelomeningocele 9.8
131 hidradenocarcinoma 9.8 KRT7 CDX2
132 acanthosis nigricans 9.7
133 hepatocellular carcinoma 9.7
134 neural tube defects 9.7
135 suppression of tumorigenicity 12 9.7
136 inflammatory bowel disease 9.7
137 spina bifida occulta 9.7
138 lymphocytic leukemia 9.7
139 neurogenic bladder 9.7
140 obstructive jaundice 9.7
141 papillary adenocarcinoma 9.7
142 gallbladder adenocarcinoma 9.7
143 choriocarcinoma 9.7
144 paraplegia 9.7
145 end stage renal failure 9.7
146 subacute delirium 9.7
147 in situ carcinoma 9.7
148 exophthalmos 9.7
149 bk-virus nephropathy 9.7
150 urachal cancer 9.7
151 abdominal wall defect 9.7
152 anus cancer 9.7 KRT7 CDX2
153 gastric tubular adenocarcinoma 9.7 KRT7 CDX2
154 stomach disease 9.7 CTNNB1 CDX2
155 polycystic liver disease 1 with or without kidney cysts 9.7 KRT7 KRT20
156 gastrointestinal system benign neoplasm 9.7 KRT7 HRAS CTNNB1
157 cell type benign neoplasm 9.7 KRT7 HRAS CTNNB1
158 sweat gland cancer 9.7 KRT7 KRT20
159 epithelial-myoepithelial carcinoma 9.6 KRT7 HRAS FBXW7
160 wilms tumor 1 9.6 KRT7 FBXW7 CTNNB1
161 lung acinar adenocarcinoma 9.6 KRT7 KRT20 CTNNB1
162 large intestine adenocarcinoma 9.6 KRT7 KRT20 CTNNB1
163 merkel cell carcinoma 9.6 KRT7 KRT20
164 basal cell carcinoma 9.6 KRT7 KRT20 CTNNB1
165 pancreatic mucinous cystadenoma 9.5 KRT7 KRT20 HRAS
166 cervical cancer 9.5 UCA1 HRAS CTNNB1
167 nasal cavity adenocarcinoma 9.5 KRT7 HRAS CDX2
168 anal canal adenocarcinoma 9.5 KRT7 HRAS CDX2
169 duodenum cancer 9.4 KRT7 HRAS CDX2
170 gastric diffuse adenocarcinoma 9.4 KRT7 KRT20 CDX2
171 thymus adenocarcinoma 9.4 KRT7 KRT20 CDX2
172 ovarian mucinous adenocarcinoma 9.4 KRT7 KRT20 CDX2
173 jejunal adenocarcinoma 9.4 KRT7 KRT20 CDX2
174 vulva adenocarcinoma 9.4 KRT7 KRT20 CDX2
175 chronic cystitis 9.4 KRT7 KRT20 CDX2
176 mucinous bronchioloalveolar adenocarcinoma 9.4 KRT7 KRT20 CDX2
177 ampulla of vater adenocarcinoma 9.4 KRT7 KRT20 CDX2
178 ovarian mucinous neoplasm 9.4 KRT7 KRT20 CDX2
179 endocervical adenocarcinoma 9.4 KRT7 KRT20 CDX2
180 cervical adenocarcinoma 9.4 KRT7 KRT20 CDX2
181 prostatic acinar adenocarcinoma 9.4 KRT7 KRT20 CDX2
182 appendix cancer 9.4 KRT7 KRT20 CDX2
183 cystic teratoma 9.4 KRT7 KRT20 CDX2
184 horseshoe kidney 9.4 KRT7 KRT20 CDX2
185 pseudomyxoma peritonei 9.4 KRT7 KRT20 CDX2
186 bronchiolo-alveolar adenocarcinoma 9.4 KRT7 KRT20 CDX2
187 intestinal obstruction 9.4 KRT7 KRT20 CDX2
188 barrett esophagus 9.4 KRT7 KRT20 CDX2
189 esophageal cancer 9.3 UCA1 HRAS CTNNB1 CDX2
190 sarcoma, synovial 9.3 KRT7 CTNNB1
191 renal cell carcinoma, nonpapillary 9.3 UCA1 KRT7 KRT20
192 pancreatic cancer 9.3 UCA1 HRAS CTNNB1 CDX2
193 bladder urothelial carcinoma 9.2 KRT7 KRT20 HRAS CTNNB1
194 gastrointestinal system cancer 9.1 KRT7 HRAS CTNNB1 CDX2
195 intrahepatic cholangiocarcinoma 9.1 KRT7 KRT20 CTNNB1 CDX2
196 appendix disease 9.0 KRT7 KRT20 HRAS CDX2
197 biliary papillomatosis 9.0 KRT7 KRT20 HRAS CDX2
198 cecum adenocarcinoma 9.0 KRT7 KRT20 HRAS CDX2
199 ampulla of vater cancer 9.0 KRT7 KRT20 HRAS CDX2
200 small intestine cancer 9.0 KRT7 KRT20 HRAS CDX2
201 adenoid cystic carcinoma 8.8 KRT7 KRT20 HRAS FBXW7 CTNNB1
202 cholangiocarcinoma 8.6 UCA1 KRT7 KRT20 CTNNB1 CDX2
203 large intestine cancer 8.2 KRT7 KRT20 HRAS FBXW7 CTNNB1 CDX2
204 colorectal cancer 7.7 UCA1 KRT7 KRT20 HRAS FBXW7 CTNNB1

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Adenocarcinoma:

46 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDX2 CTNNB1 FBXW7 HRAS

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 59, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
3
Ifosfamide Approved Phase 2 3778-73-2 3690
4
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
5
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
leucovorin Approved Phase 2 58-05-9 143 6006
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
nivolumab Approved Phase 2 946414-94-4
10
Ipilimumab Approved Phase 2 477202-00-9
11
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
12
Vinblastine Approved Phase 2 865-21-4 241903 13342
13
Daunorubicin Approved Phase 2 20830-81-3 30323
14
Durvalumab Approved, Investigational Phase 2 1428935-60-7
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
18 Piritrexim Investigational Phase 2 72732-56-0
19
Rubitecan Investigational Phase 2 91421-42-0
20
Camptothecin Experimental Phase 2 7689-03-4
21 Angiogenesis Inhibitors Phase 2
22 Angiogenesis Modulating Agents Phase 2
23 Alkylating Agents Phase 2
24 Albumin-Bound Paclitaxel Phase 2
25
Isophosphamide mustard Phase 2 0
26 Antineoplastic Agents, Alkylating Phase 2
27 topoisomerase I inhibitors Phase 2
28 Anti-Infective Agents Phase 2
29 Immunosuppressive Agents Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Antiviral Agents Phase 2
32 Antimetabolites Phase 2
33 Antimetabolites, Antineoplastic Phase 2
34 Immunologic Factors Phase 2
35 Folic Acid Antagonists Phase 2
36 Folate Phase 2
37 Vitamin B9 Phase 2
38 Vitamin B Complex Phase 2
39 Antineoplastic Agents, Phytogenic Phase 2
40 Tubulin Modulators Phase 2
41 Antimitotic Agents Phase 2
42 Topoisomerase Inhibitors Phase 2
43 Antibodies Phase 2
44 Antibodies, Monoclonal Phase 2
45 Immunoglobulins Phase 2
46 Anti-Bacterial Agents Phase 2
47
Liposomal doxorubicin Phase 2 31703
48 Antibiotics, Antitubercular Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 2
50 Dermatologic Agents Phase 2
51 Antirheumatic Agents Phase 2
52
Pancrelipase Approved, Investigational Phase 1 53608-75-6
53
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
54
Metronidazole Approved Phase 1 443-48-1 4173
55 pancreatin Phase 1
56 Cola Phase 1
57 Antiparasitic Agents Phase 1
58 Vaccines Phase 1
59 Antiprotozoal Agents Phase 1

Interventional clinical trials:

(showing 10, show less)
# Name Status NCT ID Phase Drugs
1 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
2 A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts. Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
3 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
4 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
5 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
6 A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Recruiting NCT03747419 Phase 2 Avelumab
7 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
8 Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
9 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
10 Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

41
Prostate, Lung, Colon, Skin, Liver, Lymph Node, Breast

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(showing 140, show less)
# Title Authors PMID Year
1
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. 9 38
18789486 2009
2
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 9 38
18670358 2008
3
[Expression of CDX2 in urinary bladder and urethra lesions]. 9 38
15074058 2004
4
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. 9 38
11684954 2001
5
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 9 38
10658909 2000
6
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. 9 38
9522212 1998
7
A report of orbital metastasis from a urinary bladder adenocarcinoma. 38
31332150 2019
8
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 38
31395362 2019
9
Mimickers of urothelial neoplasia. 38
30380401 2019
10
Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. 38
31317053 2019
11
Non-urothelial carcinomas of the bladder. 38
30565306 2019
12
Treating bladder adenocarcinoma. 38
30687599 2018
13
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 38
31049173 2018
14
microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. 38
29693148 2018
15
Primary bladder adenocarcinoma: Case report with long-term follow-up. 38
29785373 2018
16
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. 38
27048257 2018
17
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. 38
29203990 2017
18
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. 38
28548125 2017
19
Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features - multiple primaries versus metastatic neoplasms: a case report. 38
28494807 2017
20
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. 38
28511402 2017
21
Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. 38
28056456 2017
22
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. 38
27381065 2016
23
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. 38
27427223 2016
24
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. 38
27703678 2016
25
Cutaneous metastasis: An unusual presenting feature of urologic malignancies. 38
27453667 2016
26
Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. 38
27267922 2016
27
[Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review]. 38
27266688 2016
28
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. 38
27081650 2016
29
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. 38
26463756 2016
30
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. 38
26955660 2016
31
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. 38
27006847 2016
32
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. 38
27288750 2016
33
[A Case of Bladder Adenocarcinoma with Rectal Metastasis]. 38
26805326 2015
34
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 38
25930983 2015
35
Gall bladder Adenocarcinoma in a Young Girl. 38
26139973 2015
36
Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder. 38
25830047 2015
37
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. 38
26421206 2015
38
Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology. 38
25047418 2015
39
Serotonin and cancer: what is the link? 38
25601469 2015
40
Adenocarcinoma of the urinary bladder. 38
26309895 2015
41
En Bloc Robot-assisted Laparoscopic Partial Cystectomy, Urachal Resection, and Pelvic Lymphadenectomy for Urachal Adenocarcinoma. 38
26029004 2015
42
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. 38
24281125 2015
43
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. 38
25029122 2014
44
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. 38
24716732 2014
45
Xanthogranulomatous cholecystitis: a rare cause of digestive hemorrhage. 38
24411821 2014
46
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. 38
25040620 2014
47
The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. 38
24752337 2014
48
EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. 38
23887300 2014
49
GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. 38
24061521 2013
50
A metastatic cancer to skin in an otherwise asymptomatic young man: an unusual presentation. 38
24139375 2013
51
[Role of arginase-1 expression in distinguishing hepatocellular carcinoma from non-hepatocellular tumors]. 38
24246920 2013
52
Primary urachal mucinous adenocarcinoma of the urinary bladder. 38
23814741 2013
53
Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. 38
23348900 2013
54
Primary adenocarcinoma of the urinary bladder: differential diagnosis and clinical relevance. 38
23451748 2013
55
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. 38
23589601 2013
56
Approaches to management of adenocarcinoma following colocystoplasty. 38
23339985 2013
57
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. 38
24596525 2013
58
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. 38
22804747 2012
59
[Surgical treatment for gall bladder cancer with a confluence stone-a case report]. 38
23268000 2012
60
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. 38
23121893 2012
61
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. 38
23076693 2012
62
Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database. 38
22441574 2012
63
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. 38
22294067 2011
64
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. 38
22081531 2011
65
Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. 38
21496868 2011
66
Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers. 38
21571954 2011
67
Bladder adenocarcinoma following gastrocystoplasty. 38
20392671 2010
68
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. 38
28657060 2010
69
Calreticulin is a B cell molecular target in some gastrointestinal malignancies. 38
20030668 2010
70
The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. 38
20731252 2010
71
Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. 38
20178637 2010
72
Simultaneous penile and signet ring cell bladder carcinoma in renal transplant recipient: a first case. 38
19768347 2009
73
Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature. 38
19483630 2009
74
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. 38
19221283 2009
75
[Primary bladder adenocarcinoma in unreconstructed exstrophic bladder]. 38
19418846 2009
76
The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. 38
18978733 2009
77
[Closure of a neobladder-vaginal fistula in a patient with Studer's type neobladder using a transvaginal approach with interposition of a Martius' flap]. 38
19400447 2009
78
Serotonin used as prognostic marker of urological tumors. 38
18581119 2008
79
[Bladder adenocarcinoma. Case report]. 38
18972921 2008
80
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. 38
18604226 2008
81
Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. 38
18455631 2008
82
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. 38
18307003 2008
83
Urinary bladder adenocarcinoma arising in a spina bifida patient. 38
18022132 2007
84
Erysipeloid cutaneous metastasis from bladder carcinoma. 38
17951136 2007
85
[Primary signet ring cell bladder adenocarcinoma. Case report with a multidisciplinary therapeutical approach]. 38
18020218 2007
86
Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. 38
17721186 2007
87
[Analysis of pelvic lipomatosis and a case report of two brothers]. 38
17657258 2007
88
Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. 38
17883119 2007
89
Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses. 38
17562512 2007
90
[Bladder exstrophy adenocarcinoma in an adult woman. Case report]. 38
17484491 2007
91
Appendiceal carcinoma masquerading as recurrent urinary tract infections: case report and review of literature. 38
16904475 2006
92
Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. 38
16280666 2005
93
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. 38
15822823 2005
94
Imaging features of primary nonurachal adenocarcinoma of the bladder. 38
15505310 2004
95
[Primary adenocarcinoma of the bladder and renal transplantation]. 38
14650308 2003
96
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. 38
19861819 2003
97
Neural network-based assessment of prognostic markers and outcome prediction in bilharziasis-associated bladder cancer. 38
14518736 2003
98
Cyclin E overexpression and amplification in human tumours. 38
12845634 2003
99
[Acute renal failure as the beginning of glandular cystitis. Review of the bibliography]. 38
12918302 2003
100
Spontaneous resolution of bladder adenocarcinoma. 38
15160537 2003
101
Bladder adenocarcinoma: 31 reported cases. 38
11718635 2001
102
[Primary bladder adenocarcinoma: our experience in the last 10 years]. 38
11692800 2001
103
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. 38
11506474 2001
104
[Bladder adenocarcinoma with glandular cystitis areas]. 38
11432041 2001
105
[Adenocarcinoma of the urinary bladder: a report of 27 cases]. 38
11776628 1999
106
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. 38
10510893 1999
107
[Primary nontransitional neoplasms of the bladder]. 38
10488613 1999
108
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. 38
10332458 1999
109
Urine cytology of primary and secondary urinary bladder adenocarcinoma. 38
9915134 1998
110
Urachal adenocarcinoma. 38
12735811 1997
111
Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. 38
9477181 1997
112
Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. 38
9343322 1997
113
[Complicated urachal cyst: a difficult differential diagnosis]. 38
9273086 1997
114
A human gall-bladder signet ring cell carcinoma cell line. 38
9211524 1997
115
Transitional cell and uncommon urothelial carcinoma of renal pelvis/ureter and bladder: low incidence of human papilloma virus. 38
9198289 1997
116
Bladder adenocarcinoma during pregnancy: a case report. 38
8855078 1996
117
Adenocarcinoma of the colon simulating primary urinary bladder neoplasia. A report of nine cases. 38
8422112 1993
118
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. 38
8389497 1993
119
[Primary signet-ring cell bladder adenocarcinoma]. 38
1663328 1991
120
[Bladder adenocarcinoma of the signet-ring cell type. Report of a case]. 38
1663310 1991
121
[Bladder adenocarcinoma of urachal origin. A rare tumor]. 38
1927649 1991
122
[Primary bladder adenocarcinoma: retrospective study of 11 cases and general review]. 38
1867487 1991
123
[Bladder adenocarcinoma. Presentation of 3 new cases]. 38
1867488 1991
124
Primary adenocarcinoma of the bladder: favorable prognostic significance of deoxyribonucleic acid diploidy measured by flow cytometry. 38
2231882 1990
125
[Primary bladder adenocarcinoma of the signet-ring cell type]. 38
2166486 1990
126
[Bladder adenocarcinoma. Report of 2 new cases]. 38
2624498 1989
127
[A case of signet ring cell carcinoma of the urinary bladder]. 38
2853933 1988
128
[Primary bladder adenocarcinoma in a young girl]. 38
3066209 1988
129
Primary signet-ring cell carcinoma of bladder. 38
2446414 1987
130
Paget's disease of the groin associated with adenocarcinoma of the urinary bladder. 38
2442213 1987
131
Enhanced pancreatic and skin tumorigenesis in cabbage-fed hamsters and mice. 38
3594724 1987
132
Gallbladder adenocarcinoma: prognostic significance of tumor acid mucopolysaccharide content. 38
2946897 1986
133
Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. 38
2426474 1986
134
[Immuno-cytochemical and -histochemical localization of human keratin proteins in various kinds of cancerous lesion]. 38
6209433 1984
135
Malignant urachal lesions. 38
6361280 1984
136
[Bladder adenocarcinoma]. 38
6625692 1983
137
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). 38
6983292 1982
138
Canine bile duct carcinoma. 38
6266117 1981
139
Adenocarcinoma of the urinary bladder: histologic, cytologic and ultrastructural features in a case. 38
6942621 1981
140
[Congenital cyst of the common hepatic duct. Adenocarcinoma of the gall bladder and of the stomach (author's transl)]. 38
748356 1978

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

GO Terms for Bladder Adenocarcinoma

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

(showing 3, show less)
# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.16 FBXW7 CTNNB1
2 negative regulation of gene expression GO:0010629 9.13 HRAS FBXW7 CTNNB1
3 vasculature development GO:0001944 8.62 FBXW7 CTNNB1

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....